oppn parties Drug Manufacturing: Strictly Follow GMP To Restore Faith

News Snippets

  • The Indian envoy in Bangladesh was summoned by the country's government over the breach in the Bangladesh mission in Agartala
  • Bank account to soon have 4 nominees each
  • TMC and SP stayed away from the INDIA bloc protest over the Adani issue in the Lok Sabha
  • Delhi HC stops the police from arresting Nadeem Khan over a viral video which the police claimed promoted 'enmity'. Court says 'India's harmony not so fragile'
  • Trafiksol asked to refund IPO money by Sebi on account of alleged fraud
  • Re goes down to 84.76 against the USD but ends flat after RBI intervenes
  • Sin goods like tobacco, cigarettes and soft drinks likely to face 35% GST in the post-compensation cess era
  • Bank credit growth slows to 11% (20.6% last year) with retail oans also showing a slowdown
  • Stock markets continue their winning streak on Tuesday: Sensex jumps 597 points to 80845 and Nifty gains 181 points to 24457
  • Asian junior hockey: Defending champions India enter the finals by beating Malaysia 3-1, to play Pakistan for the title
  • Chess World title match: Ding Liren salvages a sraw in the 7th game which he almost lost
  • Experts speculate whether Ding Liren wants the world title match against D Gukesh to go into tie-break after he let off Gukesh easily in the 5th game
  • Tata Memorial Hospital and AIIMS have severely criticized former cricketer and Congress leader Navjot Singh Sidhu for claiming that his wife fought back cancer with home remedies like haldi, garlic and neem. The hospitals warned the public for not going for such unproven remedies and not delaying treatment as it could prove fatal
  • 3 persons died and scores of policemen wer injured when a survey of a mosque in Sambhal near Bareilly in UP turned violent
  • Bangladesh to review power pacts with Indian companies, including those of the Adani group
Devendra Fadnavis to be the next chief minister of Maharashtra after Eknath Shinde agrees to join the government as deputy CM
oppn parties
Drug Manufacturing: Strictly Follow GMP To Restore Faith

By A Special Correspondent
First publised on 2023-08-12 02:00:55

Centre's recent move to enforce adherence to World Health Organization (WHO)-GMP standards within the pharmaceutical sector marks a pivotal moment in the nation's quest to restore its standing as a trustworthy source of cost-effective generics. In a matter of months, a series of grave incidents has shaken the reputation of India's pharmaceutical prowess, urging the industry to urgently prioritize regulatory reform and quality assurance.

Recent global medical alerts issued by the WHO concerning Indian cough syrups and products underscore the critical need to rectify existing vulnerabilities. A series of alarming incidents across several nations has been linked to alleged contamination in Indian-manufactured syrups, eye-drops, and eye ointments. Shockingly, the deaths of children in Gambia and Uzbekistan, as well as cases in the United States and Cameroon, have been attributed to these products. Despite these concerns, Indian drug regulatory authorities have often deferred addressing core issues, relying instead on piecemeal solutions or evading complicity.

The government's directive mandates medium, small, and micro enterprises (MSMEs) engaged in pharmaceutical production to adopt good manufacturing practices (GMP) within the next 6 to 12 months. Larger companies with a turnover exceeding Rs 250 crore are required to implement these changes within six months from August 1, while those with lower turnovers have a year to do so. This strategic alignment with global WHO standards is aimed at solidifying India's position as the 'pharmacy of the world', as aptly stated by Union Health Minister Mansukh Mandaviya.

To reinforce the gravity of compliance, Minister Mandaviya has cautioned manufacturers that failure to meet these standards could lead to the revocation of licenses and substantial financial penalties. The government's commitment extends beyond mere policy changes; an intensified program of risk-based inspections will be conducted across the country to ensure that pharmaceutical companies adhere to the current GMP and quality management regulations.

Nevertheless, rectifying these challenges is no small feat. Presently, only 2,000 out of 10,500 drug manufacturing units in the country meet WHO-GMP certified global standards. Studies have exposed the unsettling reality that major pharmaceutical companies often outsource production to MSME outfits, where cost considerations often take precedence over quality. Moreover, understaffed and resource-limited state regulatory bodies struggle to oversee the operations of these firms, especially those entailing dubious operators.

The implementation of GMP has been a persistent weak point for India's pharmaceutical industry since its mandatory introduction in 2005. The government's attempts to nudge the industry towards compliance over the past two decades have yielded limited success. To genuinely elevate India's pharmaceutical reputation to global standards, a mere rule change is insufficient. The transformation requires establishing a scientific, efficient, robust, and transparent regulatory system, which in turn necessitates strong political will.